BioPharmSignal logoBioPharmSignal

Biotech News

Barinthus Bio Promotes SNAP-TI Co-inventor, Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer

Barinthus Biotherapeutics (BRNS)Barinthus BiotherapeuticsCompany update

OXFORD, United Kingdom and GERMANTOWN, Md., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio”), today announced the promotion of Geoffrey Lynn, M.D., Ph.D. to Chief Scientific Officer (CSO), effective as of December 1, 2024. Dr.

Related news

BRNSBarinthus Biotherapeutics2026-08-24 22:57 EST

Barinthus Bio Provides Update on Proposed Combination with Clywedog Therapeutics

BRNSBarinthus Biotherapeutics2026-08-06 12:00 EST

Barinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate Developments

NRIXNurix Therapeutics2026-08-20 11:00 EST

Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer

BNTXBioNTech2026-08-03 09:00 EST

BioNTech Announces Appointment of Guido Oelkers to Management Board as Chief Executive Officer

BMEABiomea Fusion2026-06-05 23:32 EST

Biomea Fusion Presents New Clinical and Translational Data for Icovamenib at the American Diabetes Association (“ADA”) 86th Scientific Sessions and Announces Expansion of Ongoing Phase I BMF-650 Study

View all latest news

Barinthus Biotherapeutics

Immune-Tolerance Therapeutics Barinthus Biotherapeutics develops immunotherapies intended to retrain the immune system in autoimmune and chronic infectious diseases. Its current internal focus is immune tolerance rather than broad immune stimulation. SNAP-TI Platform The SNAP-Tolerance Immunotherapy platform is designed to deliver...

Recent company news

BRNSBarinthus Biotherapeutics2026-08-24 22:57 EST

Barinthus Bio Provides Update on Proposed Combination with Clywedog Therapeutics

BRNSBarinthus Biotherapeutics2026-08-06 12:00 EST

Barinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate Developments

BRNSBarinthus Biotherapeutics2026-04-30 11:30 EST

Barinthus Bio Reports First Quarter 2026 Financial Results and Updates on Corporate Developments

BRNSBarinthus Biotherapeutics2026-03-13 12:00 EST

Barinthus Bio Reports Full Year 2025 Financial Results and Updates on Corporate Developments

BRNSBarinthus Biotherapeutics2025-12-10 13:00 EST

Barinthus Bio Announces Update on Phase 1 AVALON Clinical Trial of VTP-1000 for the Treatment of Celiac Disease

Stock data

Close
0.62 USD
Market cap
26.96M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States